It is a national key new product and its core technology won the second prize of National Science and Technology Progress Award. It is a targeted vasodilator that can effectively improve microcirculation disorders. It is indicated for improvement of cardiovascular and cerebrovascular microcirculation disorders, anti-thrombotic treatment after organ transplantation, hypoxemia relief in treatment of ductus dependent congenital heart diseases, and auxiliary treatment of chronic hepatitis.
Listed in the National Essential Medicines List, National Reimbursement Drug List (Category A) and National Centralized Drug Procurement List The third-generation calcium ion antagonists and the first-line antihypertensive drug recommended by authoritative Chinese and international guidelines.
Listed in the National Essential Medicines List, National Reimbursement Drug List (Category A) and National Centralized Drug Procurement List First-line antihypertensive drug recommended by authoritative Chinese and international guidelines. With dual effects of diuresis and vasodilation.